NEW ENGLAND RETINA ASSOCIATES
🇺🇸United States
Clinical Trials
6
Active:0
Completed:4
Trial Phases
3 Phases
Phase 2:2
Phase 3:1
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (50.0%)Phase 3
1 (25.0%)Phase 4
1 (25.0%)Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids
Phase 4
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- Device: Dextenza Dexamethasone ImplantDrug: Topical Prednisolone Acetate 1%
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- New England Retina Associates
- Target Recruit Count
- 30
- Registration Number
- NCT04426734
Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes
Completed
- Conditions
- Epiretinal MembraneAge Related Macular Degeneration
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- New England Retina Associates
- Target Recruit Count
- 16
- Registration Number
- NCT01846351
Ranibizumab as a Rescue Therapy for Diabetic Macular Edema
Phase 2
Withdrawn
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: injection of 0.5 mg of Intravitreal Ranibizumab
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- New England Retina Associates
- Registration Number
- NCT01253694
- Locations
- 🇺🇸
New England Retina Associates, Norwich, Connecticut, United States
Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma
Completed
- Conditions
- Choroidal Melanoma
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- New England Retina Associates
- Target Recruit Count
- 46
- Registration Number
- NCT01253759
- Locations
- 🇺🇸
New England Retina Associates, Hamden, Connecticut, United States
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
Phase 2
Completed
- Conditions
- Choroidal Melanoma
- Interventions
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- New England Retina Associates
- Target Recruit Count
- 10
- Registration Number
- NCT01251978
- Locations
- 🇺🇸
New England Retina Associates, Hamden, Connecticut, United States
- Prev
- 1
- 2
- Next
News
No news found